Beyond The Numbers: 12 Analysts Discuss Tandem Diabetes Care Stock
In the last three months, 12 analysts have published ratings on Tandem Diabetes Care (NASDAQ:TNDM), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 7 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 3 | 0 | 0 |
| 2M Ago | 1 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 1 |
Analysts have set 12-month price targets for Tandem Diabetes Care, revealing an average target of $19.78, a high estimate of $51.00, and a low estimate of $10.35. This current average represents a 44.27% decrease from the previous average price target of $35.49.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Tandem Diabetes Care among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steven Lichtman | Oppenheimer | Lowers | Outperform | $22.00 | $44.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $11.00 | $10.35 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $10.35 | $10.00 |
| Brooks O'Neil | Lake Street | Lowers | Hold | $12.00 | $75.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $51.00 | $53.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $24.00 | $59.00 |
| Danielle Antalffy | UBS | Lowers | Neutral | $17.00 | $20.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $25.00 | $45.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $13.00 | $20.00 |
| Matt O'Brien | Piper Sandler | Lowers | Neutral | $14.00 | $30.00 |
| Joanne Wuensch | Citigroup | Lowers | Sell | $14.00 | $24.00 |
| Richard Newitter | Truist Securities | Announces | Hold | $24.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tandem Diabetes Care. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tandem Diabetes Care compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Tandem Diabetes Care's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Tandem Diabetes Care analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Understanding the Numbers: Tandem Diabetes Care's Finances
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Tandem Diabetes Care's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.46% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Tandem Diabetes Care's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21.77%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Tandem Diabetes Care's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -36.32%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio stands notably higher than the industry average, reaching 3.37. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.